Home » Stocks » VRML

Vermillion, Inc. (VRML)

Jun 12, 2020 - Stock symbol was changed to AWH
Stock Price: $4.00 USD 0.00 (0.00%)
Updated Jun 11, 2020 4:00 PM EDT
Market Cap 400.75M
Revenue (ttm) 4.96M
Net Income (ttm) n/a
Shares Out 97.38M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Jun 11, 2020
Last Price $4.00
Previous Close $4.00
Change ($) 0.00
Change (%) 0.00%
Day's Open 3.93
Day's Range 4.00 - 4.75
Day's Volume 743,319
52-Week Range 0.35 - 5.78

News

Hide News
GlobeNewsWire - 5 months ago

AUSTIN, Texas, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced management will participate in the ...

GlobeNewsWire - 6 months ago

Conference Call scheduled for today, August 13th at 4:30 p.m. ET Conference Call scheduled for today, August 13th at 4:30 p.m. ET

GlobeNewsWire - 6 months ago

Conference Call scheduled for today, August 13th at 4:30 p.m. ET Conference Call scheduled for today, August 13th at 4:30 p.m. ET

GlobeNewsWire - 6 months ago

AUSTIN, Texas, July 31, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced it will report financial results for...

GlobeNewsWire - 7 months ago

AUSTIN, Texas, July 01, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today annou...

Benzinga - 8 months ago

Vermillion, Inc. (NASDAQ: VRML) shares were trading higher on Wednesday, after the company announced it completed validation of new pre-surgical test offerings with OVA1 plus, including corona...

GlobeNewsWire - 8 months ago

AUSTIN, Texas, June 10, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its...

GlobeNewsWire - 8 months ago

AUSTIN, Texas, June 09, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it is set ...

Seeking Alpha - 9 months ago

Vermillion's (VRML) CEO Valerie Palmieri on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Conference Call scheduled for today, May 14th at 4:30 p.m. ET Conference Call scheduled for today, May 14th at 4:30 p.m. ET

Seeking Alpha - 10 months ago

Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Vermillion's (VRML) CEO Valerie Palmieri on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Vermillion's (VRML) CEO Valerie Palmieri on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q4 2018 Results - Earnings Call Transcript

About VRML

Vermillion, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic ... [Read more...]

Industry
Diagnostics & Research
IPO Date
Sep 29, 2000
CEO
Valerie Barber Palmieri
Employees
52
Stock Exchange
NASDAQ
Ticker Symbol
VRML
Full Company Profile

Financial Performance

In 2019, Vermillion's revenue was $4.54 million, an increase of 48.64% compared to the previous year's $3.05 million. Losses were -$15.24 million, 34.0% more than in 2018.

Financial Statements